Sean R. Hosein is the science and medical editor of CATIE, a prominent Canadian HIV news and information resource. He has been covering HIV news since 1988. CATIE profiled Hostein in 2014 for its landmark 200th TreatmentUpdate issue.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
Researchers hope that by interacting with the toll-like receptor protein TLR-7 an experimental drug can help increase the immune system's ability to sense and attack HIV and HIV-infected cells.
Researchers found that around 90% of participants who were switched to a dual drug regimen maintained a suppressed viral load over the course of the study.
The results from this pilot study are exciting and raise many issues that need to be taken into account for future studies of broadly neutralizing antibodies.
U.S. researchers have developed PrEPmate, a text messaging service to increase PrEP adherence.
Researchers found that, overall, rates of diagnosed mental health conditions were twice as high among HIV-positive people compared with HIV-negative people.
In a study of more than 1,400 women living with HIV, nearly 30% did not achieve viral suppression and some groups of women had greater challenges with adherence and staying in care.